Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Matching Placebo Patch Clear all
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 4 Interventional

Dupilumab in the Treatment of Keloids

NCT04988022
View directory record Official record
Conditions
Keloid
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 6, 2026, 3:34 PM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

NCT05343455
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Santa Monica, California • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 6, 2026, 3:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
View directory record Official record
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Milk Patch for Eosinophilic Esophagitis

NCT02579876
View directory record Official record
Conditions
Eosinophilic Esophagitis, Milk Allergy
Interventions
Viaskin Milk 500 mcg, Viaskin Placebo
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Selegiline, Placebo (for Selegiline)
Drug
Lead sponsor
Mood and Anxiety Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

ELITE: Early Versus Late Intervention Trial With Estradiol

NCT00114517
View directory record Official record
Conditions
Atherosclerosis
Interventions
17B-estradiol, Placebo
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
Female only
Enrollment
643 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

NCT01744496
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT00490919
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine transdermal system, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Results available

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

NCT01782222
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Oxnard, California • Ormond Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days

NCT01234142
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline free base patch, placebo patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Results available

Raloxifene and Rimostil for Perimenopause-Related Depression

NCT00030147
View directory record Official record
Conditions
Perimenopausal Depression, Depression
Interventions
Raloxifene, Rimostil, Transdermal Estradiol, Placebo skin patch and placebo tablets
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
40 Years to 60 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 6, 2026, 3:34 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

NCT05886582
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Rotigotine Transdermal System [Neupro], Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
25 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Selegiline for Smoking Cessation - 1

NCT00439413
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Selegiline Transdermal Patch, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
College Park, Maryland • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231
View directory record Official record
Conditions
Relapsing Multiple Scelrosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
59
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

NCT05296629
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
27
States / cities
Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 6, 2026, 3:34 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Results available

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

NCT00531947
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Selegiline Transdermal System, Placebo
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • National City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Not applicable Interventional Results available

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing
Device · Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 6, 2026, 3:34 PM EDT